{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T02:24:08Z","timestamp":1790130248751,"version":"4.0.1"},"reference-count":192,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s40263-026-01294-9","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T10:58:22Z","timestamp":1779879502000},"page":"921-948","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The Role of Long-Acting Injectable Antipsychotics in the Early Treatment of Schizophrenia"],"prefix":"10.1007","volume":"40","author":[{"given":"Sarah Jane","family":"Harrison","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Antunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Knight","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordy","family":"Mehawej","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph U.","family":"Correll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,27]]},"reference":[{"issue":"1","key":"1294_CR1","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41537-021-00192-x","volume":"8","author":"CU Correll","year":"2022","unstructured":"Correll CU, Martin A, Patel C, Benson C, Goulding R, Kern-Sliwa J, et al. Systematic literature review of schizophrenia clinical practice guidelines on acute and maintenance management with antipsychotics. Schizophrenia. 2022;8(1):5. https:\/\/doi.org\/10.1038\/s41537-021-00192-x.","journal-title":"Schizophrenia"},{"issue":"2","key":"1294_CR2","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1001\/jamapsychiatry.2019.3360","volume":"77","author":"RA McCutcheon","year":"2020","unstructured":"McCutcheon RA, Reis Marques T, Howes OD. Schizophrenia\u2014an overview. JAMA Psychiat. 2020;77(2):201\u201310. https:\/\/doi.org\/10.1001\/jamapsychiatry.2019.3360.","journal-title":"JAMA Psychiat"},{"key":"1294_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/molecules23082087","author":"P St\u0119pnicki","year":"2018","unstructured":"St\u0119pnicki P, Kondej M, Kaczor AA. Current concepts and treatments of schizophrenia. Molecules. 2018. https:\/\/doi.org\/10.3390\/molecules23082087.","journal-title":"Molecules"},{"key":"1294_CR4","unstructured":"WHO Fact Sheet: Schizophrenia. 2022 [cited 2025 11 September]. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/schizophrenia."},{"issue":"10202","key":"1294_CR5","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/s0140-6736(19)31135-3","volume":"394","author":"M Huhn","year":"2019","unstructured":"Huhn M, Nikolakopoulou A, Schneider-Thoma J, Krause M, Samara M, Peter N, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019;394(10202):939\u201351. https:\/\/doi.org\/10.1016\/s0140-6736(19)31135-3.","journal-title":"Lancet"},{"key":"1294_CR6","doi-asserted-by":"publisher","unstructured":"Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Psychiatry. 2022;9(2):137-50. https:\/\/doi.org\/10.1016\/s2215-0366(21)00395-3.","DOI":"10.1016\/s2215-0366(21)00395-3"},{"key":"1294_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102294","volume":"65","author":"JKN Chan","year":"2023","unstructured":"Chan JKN, Correll CU, Wong CSM, Chu RST, Fung VSC, Wong GHS, et al. Life expectancy and years of potential life lost in people with mental disorders: a systematic review and meta-analysis. EClinicalMedicine. 2023;65:102294. https:\/\/doi.org\/10.1016\/j.eclinm.2023.102294.","journal-title":"EClinicalMedicine."},{"key":"1294_CR8","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1093\/epirev\/mxn001","volume":"30","author":"J McGrath","year":"2008","unstructured":"McGrath J, Saha S, Chant D, Welham J. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev. 2008;30:67\u201376. https:\/\/doi.org\/10.1093\/epirev\/mxn001.","journal-title":"Epidemiol Rev"},{"issue":"1","key":"1294_CR9","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/s41380-021-01161-7","volume":"27","author":"M Solmi","year":"2022","unstructured":"Solmi M, Radua J, Olivola M, Croce E, Soardo L, Salazar de Pablo G, et al. Age at onset of mental disorders worldwide: large-scale meta-analysis of 192 epidemiological studies. Mol Psychiatry. 2022;27(1):281\u201395. https:\/\/doi.org\/10.1038\/s41380-021-01161-7.","journal-title":"Mol Psychiatry"},{"issue":"33","key":"1294_CR10","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1192\/S0007125000297663","volume":"172","author":"M Birchwood","year":"1998","unstructured":"Birchwood M, Todd P, Jackson C. Early intervention in psychosis. The critical period hypothesis. Br J Psychiatry Suppl. 1998;172(33):53\u20139.","journal-title":"Br J Psychiatry Suppl"},{"issue":"11","key":"1294_CR11","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1016\/s0006-3223(01)01303-8","volume":"50","author":"JA Lieberman","year":"2001","unstructured":"Lieberman JA, Perkins D, Belger A, Chakos M, Jarskog F, Boteva K, et al. The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches. Biol Psychiatry. 2001;50(11):884\u201397. https:\/\/doi.org\/10.1016\/s0006-3223(01)01303-8.","journal-title":"Biol Psychiatry"},{"issue":"3","key":"1294_CR12","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1001\/archpsyc.62.3.247","volume":"62","author":"BA Palmer","year":"2005","unstructured":"Palmer BA, Pankratz VS, Bostwick JM. The lifetime risk of suicide in schizophrenia: a reexamination. Arch Gen Psychiatry. 2005;62(3):247\u201353. https:\/\/doi.org\/10.1001\/archpsyc.62.3.247.","journal-title":"Arch Gen Psychiatry"},{"issue":"4_suppl","key":"1294_CR13","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1177\/1359786810385490","volume":"24","author":"K Hor","year":"2010","unstructured":"Hor K, Taylor M. Review: Suicide and schizophrenia: a systematic review of rates and risk factors. J Psychopharmacol. 2010;24(4_suppl):81\u201390. https:\/\/doi.org\/10.1177\/1359786810385490.","journal-title":"J Psychopharmacol"},{"issue":"2","key":"1294_CR14","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1002\/wps.20994","volume":"21","author":"CU Correll","year":"2022","unstructured":"Correll CU, Solmi M, Croatto G, Schneider LK, Rohani-Montez SC, Fairley L, et al. Mortality in people with schizophrenia: a systematic review and meta-analysis of relative risk and aggravating or attenuating factors. World Psychiatry. 2022;21(2):248\u201371. https:\/\/doi.org\/10.1002\/wps.20994.","journal-title":"World Psychiatry"},{"issue":"3","key":"1294_CR15","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1097\/yco.0000000000000052","volume":"27","author":"M Nordentoft","year":"2014","unstructured":"Nordentoft M, Rasmussen J\u00d8, Melau M, Hjorth\u00f8j CR, Thorup AAE. How successful are first episode programs? A review of the evidence for specialized assertive early intervention. Curr Opin Psychiatry. 2014;27(3):167\u201372. https:\/\/doi.org\/10.1097\/yco.0000000000000052.","journal-title":"Curr Opin Psychiatry"},{"issue":"1","key":"1294_CR16","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s13033-018-0187-1","volume":"12","author":"S-U Lee","year":"2018","unstructured":"Lee S-U, Soh M, Ryu V, Kim C-E, Park S, Roh S, et al. Risk factors for relapse in patients with first-episode schizophrenia: analysis of the Health Insurance Review and Assessment Service data from 2011 to 2015. Int J Ment Health Syst. 2018;12(1):9. https:\/\/doi.org\/10.1186\/s13033-018-0187-1.","journal-title":"Int J Ment Health Syst."},{"issue":"9","key":"1294_CR17","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.euroneuro.2017.06.011","volume":"27","author":"Y Zhu","year":"2017","unstructured":"Zhu Y, Li C, Huhn M, Rothe P, Krause M, Bighelli I, et al. How well do patients with a first episode of schizophrenia respond to antipsychotics: a systematic review and meta-analysis. Eur Neuropsychopharmacol. 2017;27(9):835\u201344. https:\/\/doi.org\/10.1016\/j.euroneuro.2017.06.011.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"6","key":"1294_CR18","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1001\/jamapsychiatry.2018.0623","volume":"75","author":"CU Correll","year":"2018","unstructured":"Correll CU, Galling B, Pawar A, Krivko A, Bonetto C, Ruggeri M, et al. Comparison of early intervention services vs treatment as usual for early phase psychosis: a systematic review, meta-analysis, and meta-regression. JAMA Psychiat. 2018;75(6):555\u201365. https:\/\/doi.org\/10.1001\/jamapsychiatry.2018.0623.","journal-title":"JAMA Psychiat"},{"issue":"5","key":"1294_CR19","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1001\/jamapsychiatry.2018.0185","volume":"75","author":"SKW Chan","year":"2018","unstructured":"Chan SKW, Chan SWY, Pang HH, Yan KK, Hui CLM, Chang WC, et al. Association of an early intervention service for psychosis with suicide rate among patients with first-episode schizophrenia-spectrum disorders. JAMA Psychiat. 2018;75(5):458\u201364. https:\/\/doi.org\/10.1001\/jamapsychiatry.2018.0185.","journal-title":"JAMA Psychiat"},{"issue":"5","key":"1294_CR20","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1017\/S2045796014000419","volume":"24","author":"GR Bond","year":"2014","unstructured":"Bond GR, Drake RE, Luciano A. Employment and educational outcomes in early intervention programmes for early psychosis: a systematic review. Epidemiol Psychiatr Sci. 2014;24(5):446\u201357. https:\/\/doi.org\/10.1017\/S2045796014000419.","journal-title":"Epidemiol Psychiatr Sci."},{"issue":"9831","key":"1294_CR21","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1016\/s0140-6736(12)60239-6","volume":"379","author":"S Leucht","year":"2012","unstructured":"Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Salanti G, et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet. 2012;379(9831):2063\u201371. https:\/\/doi.org\/10.1016\/s0140-6736(12)60239-6.","journal-title":"Lancet"},{"issue":"2","key":"1294_CR22","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1002\/wps.20632","volume":"18","author":"T Kishimoto","year":"2019","unstructured":"Kishimoto T, Hagi K, Nitta M, Kane JM, Correll CU. Long-term effectiveness of oral second-generation antipsychotics in patients with schizophrenia and related disorders: a systematic review and meta-analysis of direct head-to-head comparisons. World Psychiatry. 2019;18(2):208\u201324. https:\/\/doi.org\/10.1002\/wps.20632.","journal-title":"World Psychiatry"},{"issue":"2","key":"1294_CR23","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/wps.20972","volume":"21","author":"G Ostuzzi","year":"2022","unstructured":"Ostuzzi G, Bertolini F, Tedeschi F, Vita G, Brambilla P, Del Fabro L, et al. Oral and long-acting antipsychotics for relapse prevention in schizophrenia-spectrum disorders: a network meta-analysis of 92 randomized trials including 22,645 participants. World Psychiatry. 2022;21(2):295\u2013307. https:\/\/doi.org\/10.1002\/wps.20972.","journal-title":"World Psychiatry"},{"issue":"2","key":"1294_CR24","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/wps.20516","volume":"17","author":"CU Correll","year":"2018","unstructured":"Correll CU, Rubio JM, Kane JM. What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia? World Psychiatry. 2018;17(2):149\u201360. https:\/\/doi.org\/10.1002\/wps.20516.","journal-title":"World Psychiatry"},{"key":"1294_CR25","doi-asserted-by":"publisher","first-page":"519","DOI":"10.2147\/NDT.S225643","volume":"16","author":"CU Correll","year":"2020","unstructured":"Correll CU, Schooler NR. Negative symptoms in schizophrenia: a review and clinical guide for recognition, assessment, and treatment. Neuropsychiatr Dis Treat. 2020;16:519\u201334. https:\/\/doi.org\/10.2147\/NDT.S225643.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"6","key":"1294_CR26","doi-asserted-by":"publisher","first-page":"664","DOI":"10.47626\/1516-4446-2021-2306","volume":"44","author":"N Jia","year":"2022","unstructured":"Jia N, Li Z, Li X, Jin M, Liu Y, Cui X, et al. Long-term effects of antipsychotics on mortality in patients with schizophrenia: a systematic review and meta-analysis. Braz J Psychiatry. 2022;44(6):664\u201373. https:\/\/doi.org\/10.47626\/1516-4446-2021-2306.","journal-title":"Braz J Psychiatry."},{"issue":"1","key":"1294_CR27","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s12888-024-05554-0","volume":"24","author":"F Mohammed","year":"2024","unstructured":"Mohammed F, Geda B, Yadeta TA, Dessie Y. Antipsychotic medication non-adherence and factors associated among patients with schizophrenia in eastern Ethiopia. BMC Psychiatry. 2024;24(1):108. https:\/\/doi.org\/10.1186\/s12888-024-05554-0.","journal-title":"BMC Psychiatry"},{"issue":"1","key":"1294_CR28","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s41537-023-00356-x","volume":"9","author":"J Guo","year":"2023","unstructured":"Guo J, Lv X, Liu Y, Kong L, Qu H, Yue W. Influencing factors of medication adherence in schizophrenic patients: a meta-analysis. Schizophrenia. 2023;9(1):31. https:\/\/doi.org\/10.1038\/s41537-023-00356-x.","journal-title":"Schizophrenia"},{"issue":"3","key":"1294_CR29","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1002\/wps.20060","volume":"12","author":"JM Kane","year":"2013","unstructured":"Kane JM, Kishimoto T, Correll CU. Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies. World Psychiatry. 2013;12(3):216\u201326. https:\/\/doi.org\/10.1002\/wps.20060.","journal-title":"World Psychiatry"},{"issue":"3","key":"1294_CR30","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1093\/schbul\/sbac014","volume":"48","author":"J Lieslehto","year":"2022","unstructured":"Lieslehto J, Tiihonen J, L\u00e4hteenvuo M, Tanskanen A, Taipale H. Primary nonadherence to antipsychotic treatment among persons with schizophrenia. Schizophr Bull. 2022;48(3):655\u201363. https:\/\/doi.org\/10.1093\/schbul\/sbac014.","journal-title":"Schizophr Bull"},{"issue":"6","key":"1294_CR31","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1176\/appi.ajp.2011.10081224","volume":"168","author":"J Tiihonen","year":"2011","unstructured":"Tiihonen J, Haukka J, Taylor M, Haddad PM, Patel MX, Korhonen P. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry. 2011;168(6):603\u20139.","journal-title":"Am J Psychiatry"},{"issue":"6","key":"1294_CR32","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1093\/schbul\/sbab063","volume":"47","author":"JM Rubio","year":"2021","unstructured":"Rubio JM, Taipale H, Tanskanen A, Correll CU, Kane JM, Tiihonen J. Long-term continuity of antipsychotic treatment for schizophrenia: a nationwide study. Schizophr Bull. 2021;47(6):1611\u201320. https:\/\/doi.org\/10.1093\/schbul\/sbab063.","journal-title":"Schizophr Bull"},{"issue":"1","key":"1294_CR33","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.schres.2012.05.007","volume":"139","author":"M Alvarez-Jimenez","year":"2012","unstructured":"Alvarez-Jimenez M, Priede A, Hetrick SE, Bendall S, Killackey E, Parker AG, et al. Risk factors for relapse following treatment for first episode psychosis: a systematic review and meta-analysis of longitudinal studies. Schizophr Res. 2012;139(1):116\u201328. https:\/\/doi.org\/10.1016\/j.schres.2012.05.007.","journal-title":"Schizophr Res"},{"key":"1294_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.695672","volume":"12","author":"D Lin","year":"2021","unstructured":"Lin D, Joshi K, Keenan A, Shepherd J, Bailey H, Berry M, et al. Associations between relapses and psychosocial outcomes in patients with schizophrenia in real-world settings in the United States. Front Psychiatry. 2021;12:695672. https:\/\/doi.org\/10.3389\/fpsyt.2021.695672.","journal-title":"Front Psychiatry."},{"issue":"11","key":"1294_CR35","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1017\/S0033291707002656","volume":"38","author":"A Malla","year":"2008","unstructured":"Malla A, Norman R, Bechard-Evans L, Schmitz N, Manchanda R, Cassidy C. Factors influencing relapse during a 2-year follow-up of first-episode psychosis in a specialized early intervention service. Psychol Med. 2008;38(11):1585\u201393. https:\/\/doi.org\/10.1017\/S0033291707002656.","journal-title":"Psychol Med"},{"issue":"1","key":"1294_CR36","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s13033-021-00464-0","volume":"15","author":"S Moges","year":"2021","unstructured":"Moges S, Belete T, Mekonen T, Menberu M. Lifetime relapse and its associated factors among people with schizophrenia spectrum disorders who are on follow up at Comprehensive Specialized Hospitals in Amhara region, Ethiopia: a cross-sectional study. Int J Ment Health Syst. 2021;15(1):42. https:\/\/doi.org\/10.1186\/s13033-021-00464-0.","journal-title":"Int J Ment Health Syst."},{"issue":"1","key":"1294_CR37","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/1471-244X-13-50","volume":"13","author":"R Emsley","year":"2013","unstructured":"Emsley R, Chiliza B, Asmal L, Harvey BH. The nature of relapse in schizophrenia. BMC Psychiatry. 2013;13(1):50. https:\/\/doi.org\/10.1186\/1471-244X-13-50.","journal-title":"BMC Psychiatry"},{"issue":"3","key":"1294_CR38","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1001\/archpsyc.56.3.241","volume":"56","author":"D Robinson","year":"1999","unstructured":"Robinson D, Woerner MG, Alvir JM, Bilder R, Goldman R, Geisler S, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry. 1999;56(3):241\u20137. https:\/\/doi.org\/10.1001\/archpsyc.56.3.241.","journal-title":"Arch Gen Psychiatry"},{"issue":"12","key":"1294_CR39","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1177\/070674371405901207","volume":"59","author":"P Tibbo","year":"2014","unstructured":"Tibbo P, Malla A, Manchanda R, Williams R, Joober R. Relapse risk assessment in early phase psychosis: the search for a reliable and valid tool. Can J Psychiatry. 2014;59(12):655\u20138. https:\/\/doi.org\/10.1177\/070674371405901207.","journal-title":"Can J Psychiatry"},{"issue":"1","key":"1294_CR40","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41537-023-00334-3","volume":"9","author":"CU Correll","year":"2023","unstructured":"Correll CU, Benson C, Emond B, Patel C, Lafeuille M-H, Lin D, et al. Comparison of clinical outcomes in patients with schizophrenia following different long-acting injectable event-driven initiation strategies. Schizophrenia. 2023;9(1):9. https:\/\/doi.org\/10.1038\/s41537-023-00334-3.","journal-title":"Schizophrenia"},{"issue":"4","key":"1294_CR41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0267808","volume":"17","author":"L Lian","year":"2022","unstructured":"Lian L, Kim DD, Procyshyn RM, C\u00e1zares D, Honer WG, Barr AM. Long-acting injectable antipsychotics for early psychosis: a comprehensive systematic review. PLoS ONE. 2022;17(4):e0267808. https:\/\/doi.org\/10.1371\/journal.pone.0267808.","journal-title":"PLoS ONE"},{"issue":"5","key":"1294_CR42","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/s2215-0366(21)00039-0","volume":"8","author":"T Kishimoto","year":"2021","unstructured":"Kishimoto T, Hagi K, Kurokawa S, Kane JM, Correll CU. Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre-post studies. Lancet Psychiatry. 2021;8(5):387\u2013404. https:\/\/doi.org\/10.1016\/s2215-0366(21)00039-0.","journal-title":"Lancet Psychiatry"},{"issue":"5","key":"1294_CR43","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.8810","volume":"4","author":"CY Huang","year":"2021","unstructured":"Huang CY, Fang SC, Shao YJ. Comparison of long-acting injectable antipsychotics with oral antipsychotics and suicide and all-cause mortality in patients with newly diagnosed schizophrenia. JAMA Netw Open. 2021;4(5):e218810. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.8810.","journal-title":"JAMA Netw Open"},{"issue":"suppl 3","key":"1294_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4088\/JCP.15032su1","volume":"77","author":"CU Correll","year":"2016","unstructured":"Correll CU, Citrome L, Haddad PM, Lauriello J, Olfson M, Calloway SM, et al. The use of long-acting injectable antipsychotics in schizophrenia: evaluating the evidence. J Clin Psychiatry. 2016;77(suppl 3):1\u201324. https:\/\/doi.org\/10.4088\/JCP.15032su1.","journal-title":"J Clin Psychiatry"},{"issue":"12","key":"1294_CR45","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1176\/appi.ajp.21121189","volume":"179","author":"M Solmi","year":"2022","unstructured":"Solmi M, Taipale H, Holm M, Tanskanen A, Mittendorfer-Rutz E, Correll CU, et al. Effectiveness of antipsychotic use for reducing risk of work disability: results from a within-subject analysis of a swedish national cohort of 21,551 patients with first-episode nonaffective psychosis. Am J Psychiatry. 2022;179(12):938\u201346. https:\/\/doi.org\/10.1176\/appi.ajp.21121189.","journal-title":"Am J Psychiatry"},{"key":"1294_CR46","doi-asserted-by":"publisher","first-page":"204512532412570","DOI":"10.1177\/20451253241257062","volume":"14","author":"G Vita","year":"2024","unstructured":"Vita G, Tavella A, Ostuzzi G, Tedeschi F, De Prisco M, Segarra R, et al. Efficacy and safety of long-acting injectable versus oral antipsychotics in the treatment of patients with early phase schizophrenia-spectrum disorders: a systematic review and meta-analysis. Ther Adv Psychopharmacol. 2024;14:20451253241257064.","journal-title":"Ther Adv Psychopharmacol."},{"issue":"4","key":"1294_CR47","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1097\/JCP.0000000000001225","volume":"40","author":"J-P Lindenmayer","year":"2020","unstructured":"Lindenmayer J-P, Glick ID, Talreja H, Underriner M. Persistent barriers to the use of long-acting injectable antipsychotics for the treatment of schizophrenia. J Clin Psychopharmacol. 2020;40(4):346\u20139.","journal-title":"J Clin Psychopharmacol"},{"issue":"4","key":"1294_CR48","doi-asserted-by":"publisher","first-page":"232","DOI":"10.9740\/mhc.2022.08.232","volume":"12","author":"S Schwartz","year":"2022","unstructured":"Schwartz S, Carilli C, Mian T, Ruekert L, Kumar A. Attitudes and perceptions about the use of long-acting injectable antipsychotics among behavioral health practitioners. Ment Health Clin. 2022;12(4):232\u201340. https:\/\/doi.org\/10.9740\/mhc.2022.08.232.","journal-title":"Ment Health Clin."},{"key":"1294_CR49","doi-asserted-by":"publisher","first-page":"531","DOI":"10.2147\/ndt.s395383","volume":"19","author":"R Milz","year":"2023","unstructured":"Milz R, Benson C, Knight K, Antunes J, Najarian D, Lopez Rengel PM, et al. The effect of longer dosing intervals for long-acting injectable antipsychotics on outcomes in schizophrenia. Neuropsychiatr Dis Treat. 2023;19:531\u201345. https:\/\/doi.org\/10.2147\/ndt.s395383.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"11","key":"1294_CR50","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1007\/s40263-021-00861-6","volume":"35","author":"JM Kane","year":"2021","unstructured":"Kane JM, McEvoy JP, Correll CU, Llorca P-M. Controversies surrounding the use of long-acting injectable antipsychotic medications for the treatment of patients with schizophrenia. CNS Drugs. 2021;35(11):1189\u2013205. https:\/\/doi.org\/10.1007\/s40263-021-00861-6.","journal-title":"CNS Drugs"},{"issue":"4","key":"1294_CR51","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1080\/14656566.2023.2181073","volume":"24","author":"PM Haddad","year":"2023","unstructured":"Haddad PM, Correll CU. Long-acting antipsychotics in the treatment of schizophrenia: opportunities and challenges. Expert Opin Pharmacother. 2023;24(4):473\u201393. https:\/\/doi.org\/10.1080\/14656566.2023.2181073.","journal-title":"Expert Opin Pharmacother"},{"key":"1294_CR52","doi-asserted-by":"publisher","first-page":"3915","DOI":"10.2147\/prbm.s371991","volume":"15","author":"I Riboldi","year":"2022","unstructured":"Riboldi I, Cavaleri D, Capogrosso CA, Crocamo C, Bartoli F, Carr\u00e0 G. Practical guidance for the use of long-acting injectable antipsychotics in the treatment of schizophrenia. Psychol Res Behav Manag. 2022;15:3915\u201329. https:\/\/doi.org\/10.2147\/prbm.s371991.","journal-title":"Psychol Res Behav Manag"},{"issue":"5","key":"1294_CR53","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1177\/2045125314540297","volume":"4","author":"S Brissos","year":"2014","unstructured":"Brissos S, Veguilla MR, Taylor D, Balanz\u00e1-Martinez V. The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal. Ther Adv Psychopharmacol. 2014;4(5):198\u2013219. https:\/\/doi.org\/10.1177\/2045125314540297.","journal-title":"Ther Adv Psychopharmacol."},{"issue":"13","key":"1294_CR54","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1080\/14656566.2023.2228686","volume":"24","author":"M H\u00f8jlund","year":"2023","unstructured":"H\u00f8jlund M, Correll CU. Switching to long-acting injectable antipsychotics: pharmacological considerations and practical approaches. Expert Opin Pharmacother. 2023;24(13):1463\u201389. https:\/\/doi.org\/10.1080\/14656566.2023.2228686.","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"1294_CR55","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s40263-020-00779-5","volume":"35","author":"CU Correll","year":"2021","unstructured":"Correll CU, Kim E, Sliwa JK, Hamm W, Gopal S, Mathews M, et al. Pharmacokinetic characteristics of long-acting injectable antipsychotics for schizophrenia: an overview. CNS Drugs. 2021;35(1):39\u201359. https:\/\/doi.org\/10.1007\/s40263-020-00779-5.","journal-title":"CNS Drugs"},{"issue":"2","key":"1294_CR56","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.rpsm.2018.03.006","volume":"12","author":"C Arango","year":"2019","unstructured":"Arango C, Baeza I, Bernardo M, Ca\u00f1as F, de Dios C, D\u00edaz-Mars\u00e1 M, et al. Long-acting injectable antipsychotics for the treatment of schizophrenia in Spain. Rev Psiquiatr Salud Ment (Engl Ed). 2019;12(2):92\u2013105. https:\/\/doi.org\/10.1016\/j.rpsm.2018.03.006.","journal-title":"Rev Psiquiatr Salud Ment (Engl Ed)."},{"issue":"4","key":"1294_CR57","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.euroneuro.2014.01.014","volume":"24","author":"MX Patel","year":"2014","unstructured":"Patel MX, Bishara D, Jayakumar S, Zalewska K, Shiers D, Crawford MJ, et al. Quality of prescribing for schizophrenia: evidence from a national audit in England and Wales. Eur Neuropsychopharmacol. 2014;24(4):499\u2013509. https:\/\/doi.org\/10.1016\/j.euroneuro.2014.01.014.","journal-title":"Eur Neuropsychopharmacol"},{"key":"1294_CR58","doi-asserted-by":"publisher","DOI":"10.3390\/jpm12030441","author":"S Reymann","year":"2022","unstructured":"Reymann S, Schoretsanitis G, Egger ST, Mohonko A, Kirschner M, Vetter S, et al. Use of long-acting injectable antipsychotics in inpatients with schizophrenia spectrum disorder in an academic psychiatric hospital in Switzerland. J Pers Med. 2022. https:\/\/doi.org\/10.3390\/jpm12030441.","journal-title":"J Pers Med."},{"issue":"11","key":"1294_CR59","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1176\/appi.ps.20220586","volume":"74","author":"SR Bunting","year":"2023","unstructured":"Bunting SR, Chalmers K, Yohanna D, Lee R. Prescription of long-acting injectable antipsychotic medications among outpatient mental health care service providers. Psychiatr Serv. 2023;74(11):1146\u201353. https:\/\/doi.org\/10.1176\/appi.ps.20220586.","journal-title":"Psychiatr Serv"},{"key":"1294_CR60","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1140969","author":"Y Liu","year":"2023","unstructured":"Liu Y, Patterson ME, Sahil S, Stoner SC. Inpatient prescribing patterns of long-acting injectables and their oral or short-acting injectable equivalent formulations. Front Pharmacol. 2023. https:\/\/doi.org\/10.3389\/fphar.2023.1140969.","journal-title":"Front Pharmacol"},{"issue":"3","key":"1294_CR61","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1177\/07067437211055413","volume":"67","author":"O Agid","year":"2022","unstructured":"Agid O, Remington G, Fung C, Nightingale NM, Duclos M, Anger GJ. Real-world utilization patterns of long-acting injectable antipsychotics in Canada: a retrospective study. Can J Psychiatry. 2022;67(3):226\u201334. https:\/\/doi.org\/10.1177\/07067437211055413.","journal-title":"Can J Psychiatry"},{"key":"1294_CR62","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.22m14544","author":"JM Kane","year":"2023","unstructured":"Kane JM, Mychaskiw MA, Lim S, Suett M, Tian M, Rubio JM. Treatment journey from diagnosis to the successful implementation of a long-acting injectable antipsychotic agent in young adults with schizophrenia. J Clin Psychiatry. 2023. https:\/\/doi.org\/10.4088\/JCP.22m14544.","journal-title":"J Clin Psychiatry"},{"key":"1294_CR63","doi-asserted-by":"publisher","first-page":"619","DOI":"10.2147\/ppa.s127623","volume":"11","author":"D Pilon","year":"2017","unstructured":"Pilon D, Joshi K, Tandon N, Lafeuille MH, Kamstra RL, Emond B, et al. Treatment patterns in Medicaid patients with schizophrenia initiated on a first- or second-generation long-acting injectable versus oral antipsychotic. Patient Prefer Adherence. 2017;11:619\u201329. https:\/\/doi.org\/10.2147\/ppa.s127623.","journal-title":"Patient Prefer Adherence"},{"key":"1294_CR64","doi-asserted-by":"publisher","first-page":"204512532097810","DOI":"10.1177\/2045125320978102","volume":"10","author":"C Barbui","year":"2020","unstructured":"Barbui C, Bertolini F, Bartoli F, Calandra C, Callegari C, Carr\u00e0 G, et al. Reasons for initiating long-acting antipsychotics in psychiatric practice: findings from the STAR Network Depot Study. Ther Adv Psychopharmacol. 2020;10:2045125320978102. https:\/\/doi.org\/10.1177\/2045125320978102.","journal-title":"Ther Adv Psychopharmacol."},{"issue":"4","key":"1294_CR65","doi-asserted-by":"publisher","first-page":"198","DOI":"10.3371\/CSRP.MACH.061213","volume":"9","author":"A Malla","year":"2016","unstructured":"Malla A, Chue P, Jordan G, Stip E, Koczerginski D, Milliken H, et al. An exploratory, open-label, randomized trial comparing risperidone long-acting injectable with oral antipsychotic medication in the treatment of early psychosis. Clin Schizophr Relat Psychoses. 2016;9(4):198\u2013208.","journal-title":"Clin Schizophr Relat Psychoses"},{"issue":"1\u20133","key":"1294_CR66","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.schres.2015.08.015","volume":"169","author":"A Schreiner","year":"2015","unstructured":"Schreiner A, Aadamsoo K, Altamura AC, Franco M, Gorwood P, Neznanov NG, et al. Paliperidone palmitate versus oral antipsychotics in recently diagnosed schizophrenia. Schizophr Res. 2015;169(1\u20133):393\u20139.","journal-title":"Schizophr Res"},{"issue":"4","key":"1294_CR67","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1097\/nmd.0000000000000646","volume":"205","author":"CA Bossie","year":"2017","unstructured":"Bossie CA, Turkoz I, Alphs L, Mahalchick L, Fu D-J. Paliperidone palmitate once-monthly treatment in recent onset and chronic illness patients with schizoaffective disorder. J Nerv Ment Dis. 2017;205(4):324\u20138. https:\/\/doi.org\/10.1097\/nmd.0000000000000646.","journal-title":"J Nerv Ment Dis"},{"issue":"4","key":"1294_CR68","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1111\/eip.12868","volume":"14","author":"B Brown","year":"2020","unstructured":"Brown B, Turkoz I, Mancevski B, Mathews M. Evaluation of paliperidone palmitate long-acting injectable antipsychotic therapy as an early treatment option in patients with schizophrenia. Early Interv Psychiatry. 2020;14(4):428\u201338.","journal-title":"Early Interv Psychiatry"},{"issue":"8","key":"1294_CR69","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1080\/14656566.2016.1174692","volume":"17","author":"L Hargarter","year":"2016","unstructured":"Hargarter L, Bergmans P, Cherubin P, Keim S, Conca A, Serrano-Blanco A, et al. Once-monthly paliperidone palmitate in recently diagnosed and chronic non-acute patients with schizophrenia. Expert Opin Pharmacother. 2016;17(8):1043\u201353.","journal-title":"Expert Opin Pharmacother"},{"issue":"2","key":"1294_CR70","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1080\/10401230701332931","volume":"19","author":"RA Lasser","year":"2007","unstructured":"Lasser RA, Bossie CA, Zhu Y, Locklear JC, Kane JM. Long-acting risperidone in young adults with early schizophrenia or schizoaffective illness. Ann Clin Psychiatry. 2007;19(2):65\u201371.","journal-title":"Ann Clin Psychiatry"},{"issue":"2","key":"1294_CR71","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1097\/YIC.0b013e3283347cbf","volume":"25","author":"W Macfadden","year":"2010","unstructured":"Macfadden W, Bossie CA, Turkoz I, Haskins JT. Risperidone long-acting therapy in stable patients with recently diagnosed schizophrenia. Int Clin Psychopharmacol. 2010;25(2):75\u201382.","journal-title":"Int Clin Psychopharmacol"},{"key":"1294_CR72","doi-asserted-by":"publisher","first-page":"657","DOI":"10.2147\/NDT.S77778","volume":"11","author":"F Zhang","year":"2015","unstructured":"Zhang F, Si T, Chiou C-F, Harris AW, Kim CY, Jahagirdar P, et al. Efficacy, safety, and impact on hospitalizations of paliperidone palmitate in recent-onset schizophrenia. Neuropsychiatr Dis Treat. 2015;11:657\u201368.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"1294_CR73","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s40263-016-0350-7","volume":"30","author":"E Parellada","year":"2016","unstructured":"Parellada E, Bioque M. Barriers to the use of long-acting injectable antipsychotics in the management of schizophrenia. CNS Drugs. 2016;30:689\u2013701.","journal-title":"CNS Drugs"},{"issue":"1","key":"1294_CR74","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/eip.12017","volume":"8","author":"V Dubois","year":"2014","unstructured":"Dubois V, Peuskens J, Geerts P, Detraux J. Clinical outcomes of long-acting risperidone in recent versus long-term diagnosed Belgian schizophrenic patients: results from electronic Schizophrenia Treatment Adherence Registry (e-STAR) and Trial for the Initiation and Maintenance Of REmission in Schizophrenia with risperidone (TIMORES). Early Interv Psychiatry. 2014;8(1):39\u201349.","journal-title":"Early Interv Psychiatry"},{"issue":"1","key":"1294_CR75","doi-asserted-by":"publisher","first-page":"57","DOI":"10.9758\/cpn.2023.21.1.57","volume":"21","author":"S-W Kim","year":"2023","unstructured":"Kim S-W, Lee B-J, Cheon E-J, Won S-H, Jo A, Kim J-M, et al. Effectiveness of switching to long-acting injectable aripiprazole in patients with recent-onset and chronic schizophrenia. Clin Psychopharmacol Neurosci. 2023;21(1):57.","journal-title":"Clin Psychopharmacol Neurosci."},{"issue":"1","key":"1294_CR76","volume":"2012","author":"A Viala","year":"2012","unstructured":"Viala A, Cornic F, Vacheron M-N. Treatment adherence with early prescription of long-acting injectable antipsychotics in recent-onset schizophrenia. Schizophr Res Treat. 2012;2012(1):368687.","journal-title":"Schizophr Res Treat"},{"key":"1294_CR77","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.2147\/ndt.s427227","volume":"20","author":"M Sajatovic","year":"2024","unstructured":"Sajatovic M, Doring M, Lopena OJ, Johnston K, Turkoz I, Josiah N, et al. Earlier use of long-acting injectable paliperidone palmitate once-monthly versus oral antipsychotics in patients with schizophrenia: an integrated patient-level meta analysis of the PROSIPAL and PRIDE studies. Neuropsychiatr Dis Treat. 2024;20:2227\u201335. https:\/\/doi.org\/10.2147\/ndt.s427227.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"8","key":"1294_CR78","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1001\/jamapsychiatry.2015.0241","volume":"72","author":"J Berwaerts","year":"2015","unstructured":"Berwaerts J, Liu Y, Gopal S, Nuamah I, Xu H, Savitz A, et al. Efficacy and safety of the 3-month formulation of paliperidone palmitate vs placebo for relapse prevention of schizophrenia: a randomized clinical trial. JAMA Psychiat. 2015;72(8):830\u20139. https:\/\/doi.org\/10.1001\/jamapsychiatry.2015.0241.","journal-title":"JAMA Psychiat"},{"issue":"3","key":"1294_CR79","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1111\/eip.12685","volume":"13","author":"KS Bell Lynum","year":"2019","unstructured":"Bell Lynum KS, Turkoz I, Kim E. Paliperidone palmitate once-every-3-months in adults with early illness schizophrenia. Early Interv Psychiatry. 2019;13(3):667\u201372.","journal-title":"Early Interv Psychiatry"},{"key":"1294_CR80","doi-asserted-by":"publisher","first-page":"204512532412432","DOI":"10.1177\/20451253241243273","volume":"14","author":"R Sancho-Echeverria","year":"2024","unstructured":"Sancho-Echeverria R, Aymerich C, Rodr\u00edguez-S\u00e1nchez JM, Gil P, Pedruzo B, Gonz\u00e1lez-Torres M\u00c1, et al. Effect of long-acting antipsychotic treatment on psychiatric hospitalization rate in early psychosis patients: a naturalistic study. Ther Adv Psychopharmacol. 2024;14:20451253241243270.","journal-title":"Ther Adv Psychopharmacol."},{"issue":"8","key":"1294_CR81","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1001\/jamapsychiatry.2015.0270","volume":"72","author":"KL Subotnik","year":"2015","unstructured":"Subotnik KL, Casaus LR, Ventura J, Luo JS, Hellemann GS, Gretchen-Doorly D, et al. Long-acting injectable risperidone for relapse prevention and control of breakthrough symptoms after a recent first episode of schizophrenia: a randomized clinical trial. JAMA Psychiat. 2015;72(8):822\u20139.","journal-title":"JAMA Psychiat"},{"issue":"6","key":"1294_CR82","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.17006","volume":"7","author":"W Chen","year":"2024","unstructured":"Chen W, Wu CS, Liu CC, Kuo PH, Chan HY, Lin YH, et al. In-hospital use of long-acting injectable antipsychotics and readmission risk in patients with first-admission schizophrenia in Taiwan. JAMA Netw Open. 2024;7(6):e2417006. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.17006.","journal-title":"JAMA Netw Open"},{"key":"1294_CR83","doi-asserted-by":"publisher","first-page":"114277","DOI":"10.1016\/j.psychres.2021.114277","volume":"306","author":"S Lee","year":"2021","unstructured":"Lee S, Schwartz S. Adherence and persistence to long-acting injectable dopamine receptor blocking agent therapy in the United States: a systematic review and meta-analysis of cohort studies. Psychiatry Res. 2021;306:114277. https:\/\/doi.org\/10.1016\/j.psychres.2021.114277.","journal-title":"Psychiatry Res"},{"issue":"2","key":"1294_CR84","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1080\/13696998.2017.1379412","volume":"21","author":"M Greene","year":"2018","unstructured":"Greene M, Yan T, Chang E, Hartry A, Touya M, Broder MS. Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder. J Med Econ. 2018;21(2):127\u201334. https:\/\/doi.org\/10.1080\/13696998.2017.1379412.","journal-title":"J Med Econ"},{"key":"1294_CR85","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.38358","author":"A Hamina","year":"2024","unstructured":"Hamina A, Taipale H, Lieslehto J, L\u00e4hteenvuo M, Tanskanen A, Mittendorfer-Rutz E, et al. Comparative effectiveness of antipsychotics in patients with schizophrenia spectrum disorder. JAMA Netw Open. 2024. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.38358.","journal-title":"JAMA Netw Open"},{"issue":"2","key":"1294_CR86","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1007\/s12325-024-03075-6","volume":"42","author":"P Li","year":"2025","unstructured":"Li P, Geng Z, Benson C, Patel C, Doshi JA. Real-world effectiveness of long-acting injectable and oral antipsychotic agents in US medicare patients with schizophrenia. Adv Ther. 2025;42(2):1251\u201364. https:\/\/doi.org\/10.1007\/s12325-024-03075-6.","journal-title":"Adv Ther"},{"issue":"2","key":"1294_CR87","doi-asserted-by":"publisher","first-page":"56","DOI":"10.9740\/mhc.2018.03.056","volume":"8","author":"EN Titus-Lay","year":"2018","unstructured":"Titus-Lay EN, Ansara ED, Isaacs AN, Ott CA. Evaluation of adherence and persistence with oral versus long-acting injectable antipsychotics in patients with early psychosis. Ment Health Clin. 2018;8(2):56\u201362.","journal-title":"Ment Health Clin."},{"issue":"9","key":"1294_CR88","doi-asserted-by":"publisher","first-page":"754","DOI":"10.18553\/jmcp.2015.21.9.754","volume":"21","author":"SC Marcus","year":"2015","unstructured":"Marcus SC, Zummo J, Pettit AR, Stoddard J, Doshi JA. Antipsychotic adherence and rehospitalization in schizophrenia patients receiving oral versus long-acting injectable antipsychotics following hospital discharge. J Manag Care Spec Pharm. 2015;21(9):754\u201368. https:\/\/doi.org\/10.18553\/jmcp.2015.21.9.754.","journal-title":"J Manag Care Spec Pharm"},{"issue":"3","key":"1294_CR89","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/s2215-0366(23)00005-6","volume":"10","author":"I Winter-van Rossum","year":"2023","unstructured":"Winter-van Rossum I, Weiser M, Galderisi S, Leucht S, Bitter I, Glenth\u00f8j B, et al. Efficacy of oral versus long-acting antipsychotic treatment in patients with early phase schizophrenia in Europe and Israel: a large-scale, open-label, randomised trial (EULAST). Lancet Psychiatry. 2023;10(3):197\u2013208. https:\/\/doi.org\/10.1016\/s2215-0366(23)00005-6.","journal-title":"Lancet Psychiatry"},{"issue":"7","key":"1294_CR90","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/S2215-0366(23)00069-X","volume":"10","author":"JM Kane","year":"2023","unstructured":"Kane JM, Kishimoto T, Achtyes E, Rubio J, Correll C. The use of long-acting injectables in early phase schizophrenia. Lancet Psychiatry. 2023;10(7):480\u20131. https:\/\/doi.org\/10.1016\/S2215-0366(23)00069-X.","journal-title":"Lancet Psychiatry"},{"issue":"7","key":"1294_CR91","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/S2215-0366(23)00180-3","volume":"10","author":"J Tiihonen","year":"2023","unstructured":"Tiihonen J. The use of long-acting injectables in early phase schizophrenia. Lancet Psychiatry. 2023;10(7):481\u20132. https:\/\/doi.org\/10.1016\/S2215-0366(23)00180-3.","journal-title":"Lancet Psychiatry"},{"issue":"7","key":"1294_CR92","doi-asserted-by":"publisher","first-page":"e2224163","DOI":"10.1001\/jamanetworkopen.2022.24163","volume":"5","author":"Y Wei","year":"2022","unstructured":"Wei Y, Yan VKC, Kang W, Wong ICK, Castle DJ, Gao L, et al. Association of long-acting injectable antipsychotics and oral antipsychotics with disease relapse, health care use, and adverse events among people with schizophrenia. JAMA Netw Open. 2022;5(7):e2224163. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.24163.","journal-title":"JAMA Netw Open"},{"issue":"4","key":"1294_CR93","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1097\/yic.0000000000000452","volume":"38","author":"JM Kane","year":"2023","unstructured":"Kane JM, Chen A, Lim S, Mychaskiw MA, Tian M, Wang Y, et al. Early versus late administration of long-acting injectable antipsychotic agents among patients with newly diagnosed schizophrenia: an analysis of a commercial claims database. Int Clin Psychopharmacol. 2023;38(4):240\u20138. https:\/\/doi.org\/10.1097\/yic.0000000000000452.","journal-title":"Int Clin Psychopharmacol"},{"issue":"7","key":"1294_CR94","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1080\/03007995.2019.1571295","volume":"35","author":"J Munday","year":"2019","unstructured":"Munday J, Greene M, Chang E, Hartry A, Yan T, Broder MS. Early initiation of long-acting injectable antipsychotic treatment is associated with lower hospitalization rates and healthcare costs in patients with schizophrenia: real-world evidence from US claims data. Curr Med Res Opin. 2019;35(7):1231\u20139.","journal-title":"Curr Med Res Opin"},{"issue":"9","key":"1294_CR95","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1185\/03007990903149306","volume":"25","author":"J Olivares","year":"2009","unstructured":"Olivares J, Peuskens J, Pecenak J, Resseler S, Jacobs A, Akhras K, et al. Clinical and resource-use outcomes of risperidone long-acting injection in recent and long-term diagnosed schizophrenia patients: results from a multinational electronic registry. Curr Med Res Opin. 2009;25(9):2197\u2013206.","journal-title":"Curr Med Res Opin"},{"issue":"6","key":"1294_CR96","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1111\/eip.13116","volume":"15","author":"W Shin","year":"2021","unstructured":"Shin W, Lee DH, Kim MK, Lee SH, Cho DY, Bang M. Clinical effectiveness of early treatment with paliperidone palmitate in schizophrenia: a retrospective real-world study in South Korea. Early Interv Psychiatry. 2021;15(6):1759\u201367.","journal-title":"Early Interv Psychiatry"},{"issue":"1","key":"1294_CR97","doi-asserted-by":"publisher","first-page":"118","DOI":"10.9758\/cpn.2022.20.1.118","volume":"20","author":"V Peitl","year":"2022","unstructured":"Peitl V, Margeti\u0107 BA, Vidrih B, Karlovi\u0107 D. The impact of long-acting paliperidone in reducing hospitalizations and clinical severity in recent onset schizophrenia: a mirror-image study in real-world clinical setting. Clin Psychopharmacol Neurosci. 2022;20(1):118\u201325. https:\/\/doi.org\/10.9758\/cpn.2022.20.1.118.","journal-title":"Clin Psychopharmacol Neurosci."},{"issue":"5","key":"1294_CR98","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1080\/14656566.2021.2023496","volume":"23","author":"MP Garcia-Portilla","year":"2022","unstructured":"Garcia-Portilla MP, Benito Ruiz A, Gomez Robina F, Garcia Dorado M, Lopez Rengel PM. Impact on functionality of the paliperidone palmitate three-month formulation in patients with a recent diagnosis of schizophrenia: a real-world observational prospective study. Expert Opin Pharmacother. 2022;23(5):629\u201338.","journal-title":"Expert Opin Pharmacother"},{"issue":"3","key":"1294_CR99","doi-asserted-by":"publisher","first-page":"293","DOI":"10.18553\/jmcp.2023.22191","volume":"29","author":"A Basu","year":"2023","unstructured":"Basu A, Patel C, Fu AZ, Brown B, Mavros P, Benson C. Real-world calibration and transportability of the Disease Recovery Evaluation and Modification (DREaM) randomized clinical trial in adult Medicaid beneficiaries with recent-onset schizophrenia. J Manag Care Spec Pharm. 2023;29(3):293\u2013302. https:\/\/doi.org\/10.18553\/jmcp.2023.22191.","journal-title":"J Manag Care Spec Pharm"},{"issue":"3","key":"1294_CR100","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1080\/13696998.2018.1560749","volume":"22","author":"JW Choon","year":"2019","unstructured":"Choon JW, Wu DB, Chong H, Lo WT, Chong CS, Chung W, et al. Real-world evidence of improved healthcare utilization in patients with schizophrenia or schizoaffective disorder after early treatment of paliperidone palmitate once-monthly treatment in Hong Kong. J Med Econ. 2019;22(3):273\u20139.","journal-title":"J Med Econ"},{"issue":"4","key":"1294_CR101","doi-asserted-by":"publisher","first-page":"41243","DOI":"10.4088\/JCP.21r14153","volume":"83","author":"S-C Fang","year":"2022","unstructured":"Fang S-C, Huang C-Y, Shao Y-HJ. Long-term outcomes of early use of long-acting injectable antipsychotics in schizophrenia. J Clin Psychiatry. 2022;83(4):41243.","journal-title":"J Clin Psychiatry"},{"issue":"6","key":"1294_CR102","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1111\/eip.12770","volume":"13","author":"M Horvitz-Lennon","year":"2019","unstructured":"Horvitz-Lennon M, Predmore Z, Orr P, Hanson M, Hillestad R, Durkin M, et al. Simulated long-term outcomes of early use of long-acting injectable antipsychotics in early schizophrenia. Early Interv Psychiatry. 2019;13(6):1357\u201365.","journal-title":"Early Interv Psychiatry"},{"issue":"1","key":"1294_CR103","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s40263-022-00976-4","volume":"37","author":"S Pappa","year":"2023","unstructured":"Pappa S, Barnett J, Mason K. A 10-year observational study of the use, acceptability and effectiveness of long-acting paliperidone palmitate: implications for clinical decision making. CNS Drugs. 2023;37(1):107\u201316.","journal-title":"CNS Drugs"},{"key":"1294_CR104","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.2147\/NDT.S191803","volume":"15","author":"T Si","year":"2019","unstructured":"Si T, Zhuo J, Feng Y, Lu H, Hong D, Zhang L. Long-term efficacy and safety of paliperidone palmitate once-monthly in Chinese patients with recent-onset schizophrenia. Neuropsychiatr Dis Treat. 2019;15:1685\u201394.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"1294_CR105","doi-asserted-by":"publisher","first-page":"204512532311952","DOI":"10.1177\/20451253231195258","volume":"13","author":"R Emsley","year":"2023","unstructured":"Emsley R. Antipsychotics and structural brain changes: could treatment adherence explain the discrepant findings? Ther Adv Psychopharmacol. 2023;13:20451253231195256. https:\/\/doi.org\/10.1177\/20451253231195258.","journal-title":"Ther Adv Psychopharmacol."},{"key":"1294_CR106","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.schres.2017.12.010","volume":"197","author":"H Taipale","year":"2018","unstructured":"Taipale H, Mittendorfer-Rutz E, Alexanderson K, Majak M, Meht\u00e4l\u00e4 J, Hoti F, et al. Antipsychotics and mortality in a nationwide cohort of 29,823 patients with schizophrenia. Schizophr Res. 2018;197:274\u201380. https:\/\/doi.org\/10.1016\/j.schres.2017.12.010.","journal-title":"Schizophr Res"},{"issue":"2\u20133","key":"1294_CR107","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.schres.2016.07.018","volume":"176","author":"F Misawa","year":"2016","unstructured":"Misawa F, Kishimoto T, Hagi K, Kane JM, Correll CU. Safety and tolerability of long-acting injectable versus oral antipsychotics: a meta-analysis of randomized controlled studies comparing the same antipsychotics. Schizophr Res. 2016;176(2\u20133):220\u201330. https:\/\/doi.org\/10.1016\/j.schres.2016.07.018.","journal-title":"Schizophr Res"},{"key":"1294_CR108","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.schres.2022.02.019","volume":"243","author":"L Alphs","year":"2022","unstructured":"Alphs L, Brown B, Turkoz I, Baker P, Fu D-J, Nuechterlein KH. The Disease Recovery Evaluation and Modification (DREaM) study: effectiveness of paliperidone palmitate versus oral antipsychotics in patients with recent-onset schizophrenia or schizophreniform disorder. Schizophr Res. 2022;243:86\u201397. https:\/\/doi.org\/10.1016\/j.schres.2022.02.019.","journal-title":"Schizophr Res"},{"issue":"1","key":"1294_CR109","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1093\/schbul\/sbad089","volume":"50","author":"D Wang","year":"2024","unstructured":"Wang D, Schneider-Thoma J, Siafis S, Burschinski A, Dong S, Wu H, et al. Long-Acting Injectable Second-Generation Antipsychotics vs Placebo and Their Oral Formulations in Acute Schizophrenia: A Systematic Review and Meta-Analysis of Randomized-Controlled-Trials. Schizophr Bull. 2024;50(1):132\u201344. https:\/\/doi.org\/10.1093\/schbul\/sbad089.","journal-title":"Schizophr Bull"},{"key":"1294_CR110","doi-asserted-by":"publisher","first-page":"375","DOI":"10.2147\/ndt.s32581","volume":"8","author":"JK Sliwa","year":"2012","unstructured":"Sliwa JK, Bossie CA, Fu DJ, Turkoz I, Alphs L. Long-term tolerability of once-monthly injectable paliperidone palmitate in subjects with recently diagnosed schizophrenia. Neuropsychiatr Dis Treat. 2012;8:375\u201385. https:\/\/doi.org\/10.2147\/ndt.s32581.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"3","key":"1294_CR111","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1097\/JCP.0b013e3182549259","volume":"32","author":"D Cohen","year":"2012","unstructured":"Cohen D, Bonnot O, Bodeau N, Consoli A, Laurent C. Adverse effects of second-generation antipsychotics in children and adolescents: a Bayesian meta-analysis. J Clin Psychopharmacol. 2012;32(3):309\u201316. https:\/\/doi.org\/10.1097\/JCP.0b013e3182549259.","journal-title":"J Clin Psychopharmacol"},{"issue":"2","key":"1294_CR112","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s40272-013-0016-6","volume":"15","author":"NB Almandil","year":"2013","unstructured":"Almandil NB, Liu Y, Murray ML, Besag FM, Aitchison KJ, Wong IC. Weight gain and other metabolic adverse effects associated with atypical antipsychotic treatment of children and adolescents: a systematic review and meta-analysis. Paediatr Drugs. 2013;15(2):139\u201350. https:\/\/doi.org\/10.1007\/s40272-013-0016-6.","journal-title":"Paediatr Drugs"},{"issue":"1","key":"1294_CR113","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jaac.2014.10.002","volume":"54","author":"KG Jensen","year":"2015","unstructured":"Jensen KG, Juul K, Fink-Jensen A, Correll CU, Pagsberg AK. Corrected QT changes during antipsychotic treatment of children and adolescents: a systematic review and meta-analysis of clinical trials. J Am Acad Child Adolesc Psychiatry. 2015;54(1):25\u201336. https:\/\/doi.org\/10.1016\/j.jaac.2014.10.002.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"9","key":"1294_CR114","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.jaac.2014.04.023","volume":"53","author":"RE Nielsen","year":"2014","unstructured":"Nielsen RE, Laursen MF, Vernal DL, Bisgaard C, Jakobsen H, Steinhausen HC, et al. Risk of diabetes in children and adolescents exposed to antipsychotics: a nationwide 12-year case-control study. J Am Acad Child Adolesc Psychiatry. 2014;53(9):971-9.e6. https:\/\/doi.org\/10.1016\/j.jaac.2014.04.023.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"2","key":"1294_CR115","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1089\/cap.2024.0050","volume":"35","author":"AM Scharko","year":"2025","unstructured":"Scharko AM, Sieracki R, Mireski SJ. Long-acting injectable antipsychotic medication use in youth: a systematic review of the literature along with MedWatch safety data and prescriber attitudes. J Child Adolesc Psychopharmacol. 2025;35(2):69\u201379. https:\/\/doi.org\/10.1089\/cap.2024.0050.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"5","key":"1294_CR116","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s40263-021-00815-y","volume":"35","author":"D Lin","year":"2021","unstructured":"Lin D, Thompson-Leduc P, Ghelerter I, Nguyen H, Lafeuille MH, Benson C, et al. Real-world evidence of the clinical and economic impact of long-acting injectable versus oral antipsychotics among patients with schizophrenia in the United States: a systematic review and meta-analysis. CNS Drugs. 2021;35(5):469\u201381. https:\/\/doi.org\/10.1007\/s40263-021-00815-y.","journal-title":"CNS Drugs"},{"issue":"10","key":"1294_CR117","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1007\/s40263-021-00849-2","volume":"35","author":"J Lauriello","year":"2021","unstructured":"Lauriello J, Weiden PJ, Gleeson CD, Shah A, Boulanger L, Jariwala-Parikh K, et al. Real-world outcomes and costs following 6 months of treatment with the long-acting injectable (LAI) aripiprazole lauroxil for the treatment of schizophrenia. CNS Drugs. 2021;35(10):1123\u201335. https:\/\/doi.org\/10.1007\/s40263-021-00849-2.","journal-title":"CNS Drugs"},{"key":"1294_CR118","doi-asserted-by":"publisher","first-page":"104455","DOI":"10.1016\/j.ajp.2025.104455","volume":"107","author":"M Kasahara-Kiritani","year":"2025","unstructured":"Kasahara-Kiritani M, Sheng C-C, Li N, Wakamatsu A, Sorensen S, Sachdev R, et al. Budget impact analysis of long-acting injections for the treatment of Schizophrenia in Japan. Asian J Psychiatr. 2025;107:104455. https:\/\/doi.org\/10.1016\/j.ajp.2025.104455.","journal-title":"Asian J Psychiatr"},{"issue":"2","key":"1294_CR119","doi-asserted-by":"publisher","first-page":"23","DOI":"10.36469\/001c.83240","volume":"10","author":"G Elsisi","year":"2023","unstructured":"Elsisi G, Ezzat M, Ramadan M. Projecting the potential budget impact analysis of paliperidone palmitate in Egyptian adult patients with schizophrenia. J Health Econ Outcomes Res. 2023;10(2):23\u20139. https:\/\/doi.org\/10.36469\/001c.83240.","journal-title":"J Health Econ Outcomes Res."},{"key":"1294_CR120","doi-asserted-by":"publisher","first-page":"519","DOI":"10.2147\/ndt.S374696","volume":"19","author":"S Bramante","year":"2023","unstructured":"Bramante S, Di Salvo G, Maina G, Rosso G. Paliperidone palmitate: a breakthrough treatment for schizophrenia? A review on patient adherence levels, healthcare resource utilization and costs. Neuropsychiatr Dis Treat. 2023;19:519\u201330. https:\/\/doi.org\/10.2147\/ndt.S374696.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"1","key":"1294_CR121","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1186\/s12888-022-03895-2","volume":"22","author":"AZ Fu","year":"2022","unstructured":"Fu AZ, Pesa JA, Lakey S, Benson C. Healthcare resource utilization and costs before and after long-acting injectable antipsychotic initiation in commercially insured young adults with schizophrenia. BMC Psychiatry. 2022;22(1):250. https:\/\/doi.org\/10.1186\/s12888-022-03895-2.","journal-title":"BMC Psychiatry"},{"issue":"4","key":"1294_CR122","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s40261-020-00900-y","volume":"40","author":"J Mahlich","year":"2020","unstructured":"Mahlich J, Olbrich K, Wilk A, Wimmer A, Wolff-Menzler C. Hospitalization rates and therapy costs of german schizophrenia patients who are initiated on long-acting injectable medication: a mirror-image study. Clin Drug Investig. 2020;40(4):355\u201375. https:\/\/doi.org\/10.1007\/s40261-020-00900-y.","journal-title":"Clin Drug Investig"},{"issue":"6","key":"1294_CR123","doi-asserted-by":"publisher","first-page":"747","DOI":"10.4103\/psychiatry.IndianJPsychiatry_670_19","volume":"62","author":"V Raghavan","year":"2020","unstructured":"Raghavan V, Cherubal AG, John S, Padmavati R. Comparison of cost-effectiveness of long-acting depot injection antipsychotics and oral antipsychotics in patients with schizophrenia in a rural community in South India. Indian J Psychiatry. 2020;62(6):747\u20138. https:\/\/doi.org\/10.4103\/psychiatry.IndianJPsychiatry_670_19.","journal-title":"Indian J Psychiatry."},{"issue":"1","key":"1294_CR124","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1186\/s12888-022-04075-y","volume":"22","author":"KO Wong","year":"2022","unstructured":"Wong KO, Klarenbach SW, Martins KJB, Chue P, Dursun SM, Snaterse M, et al. Health resource utilization and cost before versus after initiation of second-generation long-acting injectable antipsychotics among adults with schizophrenia in Alberta, Canada: a retrospective, observational single-arm study. BMC Psychiatry. 2022;22(1):444. https:\/\/doi.org\/10.1186\/s12888-022-04075-y.","journal-title":"BMC Psychiatry"},{"issue":"4","key":"1294_CR125","doi-asserted-by":"publisher","first-page":"662","DOI":"10.9758\/cpn.24.1206","volume":"22","author":"S Chi","year":"2024","unstructured":"Chi S, Ko JK, Jeong HG, Han C, Lee MS. The real-world effect of long-acting injectable antipsychotics on annual medical costs of Korean schizophrenia patients. Clin Psychopharmacol Neurosci. 2024;22(4):662\u20138. https:\/\/doi.org\/10.9758\/cpn.24.1206.","journal-title":"Clin Psychopharmacol Neurosci."},{"issue":"3","key":"1294_CR126","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1176\/appi.ajp.2016.16050503","volume":"174","author":"OD Howes","year":"2017","unstructured":"Howes OD, McCutcheon R, Agid O, de Bartolomeis A, van Beveren NJ, Birnbaum ML, et al. Treatment-resistant schizophrenia: treatment response and resistance in psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology. Am J Psychiatry. 2017;174(3):216\u201329. https:\/\/doi.org\/10.1176\/appi.ajp.2016.16050503.","journal-title":"Am J Psychiatry"},{"issue":"1","key":"1294_CR127","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-013881","volume":"7","author":"D Keating","year":"2017","unstructured":"Keating D, McWilliams S, Schneider I, Hynes C, Cousins G, Strawbridge J, et al. Pharmacological guidelines for schizophrenia: a systematic review and comparison of recommendations for the first episode. BMJ Open. 2017;7(1):e013881. https:\/\/doi.org\/10.1136\/bmjopen-2016-013881.","journal-title":"BMJ Open"},{"key":"1294_CR128","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.2147\/NDT.S167394","volume":"14","author":"M Sajatovic","year":"2018","unstructured":"Sajatovic M, Ross R, Legacy SN, Correll CU, Kane JM, DiBiasi F, et al. Identifying patients and clinical scenarios for use of long-acting injectable antipsychotics\u2014expert consensus survey part 1. Neuropsychiatr Dis Treat. 2018;14:1463\u201374. https:\/\/doi.org\/10.2147\/NDT.S167394.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"1","key":"1294_CR129","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1186\/s12888-023-04928-0","volume":"23","author":"C Arango","year":"2023","unstructured":"Arango C, Fagiolini A, Gorwood P, Kane JM, Diaz-Mendoza S, Sahota N, et al. Delphi panel to obtain clinical consensus about using long-acting injectable antipsychotics to treat first-episode and early phase schizophrenia: treatment goals and approaches to functional recovery. BMC Psychiatry. 2023;23(1):453. https:\/\/doi.org\/10.1186\/s12888-023-04928-0.","journal-title":"BMC Psychiatry"},{"issue":"5","key":"1294_CR130","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/S2215-0366(25)00031-8","volume":"12","author":"RA McCutcheon","year":"2025","unstructured":"McCutcheon RA, Pillinger T, Varvari I, Halstead S, Ayinde OO, Crossley NA, et al. INTEGRATE: international guidelines for the algorithmic treatment of schizophrenia. Lancet Psychiatry. 2025;12(5):384\u201394. https:\/\/doi.org\/10.1016\/S2215-0366(25)00031-8.","journal-title":"Lancet Psychiatry"},{"issue":"5_suppl","key":"1294_CR131","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1177\/088740341305805s03","volume":"58","author":"S Iyer","year":"2013","unstructured":"Iyer S, Banks N, Roy M-A, Tibbo P, Williams R, Manchanda R, et al. A qualitative study of experiences with and perceptions regarding long-acting injectable antipsychotics: part I\u2014patient perspectives. Can J Psychiatry. 2013;58(5_suppl):14\u201322.","journal-title":"Can J Psychiatry"},{"issue":"2","key":"1294_CR132","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1002\/npr2.12435","volume":"44","author":"Y Oguchi","year":"2024","unstructured":"Oguchi Y, Miyake N, Ando K. Barriers to long-acting injectable atypical antipsychotic use in Japan: Insights from a comparative psychiatrist survey. Neuropsychopharmacol Rep. 2024;44(2):417\u201323. https:\/\/doi.org\/10.1002\/npr2.12435.","journal-title":"Neuropsychopharmacol Rep."},{"issue":"5","key":"1294_CR133","doi-asserted-by":"publisher","first-page":"270","DOI":"10.9740\/mhc.2022.10.270","volume":"12","author":"AM VandenBerg","year":"2022","unstructured":"VandenBerg AM. An update on recently approved long-acting injectable second-generation antipsychotics: knowns and unknowns regarding their use. Ment Health Clin. 2022;12(5):270\u201381. https:\/\/doi.org\/10.9740\/mhc.2022.10.270.","journal-title":"Ment Health Clin."},{"issue":"1","key":"1294_CR134","doi-asserted-by":"publisher","DOI":"10.1017\/s1092852925100503","volume":"30","author":"CU Correll","year":"2025","unstructured":"Correll CU. Long-acting injectable antipsychotics for patients with first-episode and early phase schizophrenia: still not considered often enough. CNS Spectr. 2025;30(1):e66. https:\/\/doi.org\/10.1017\/s1092852925100503.","journal-title":"CNS Spectr"},{"issue":"5 Suppl 1","key":"1294_CR135","doi-asserted-by":"publisher","first-page":"23S","DOI":"10.1177\/088740341305805s04","volume":"58","author":"S Iyer","year":"2013","unstructured":"Iyer S, Banks N, Roy MA, Tibbo P, Williams R, Manchanda R, et al. A qualitative study of experiences with and perceptions regarding long-acting injectable antipsychotics: part II\u2014physician perspectives. Can J Psychiatry. 2013;58(5 Suppl 1):23S-S29. https:\/\/doi.org\/10.1177\/088740341305805s04.","journal-title":"Can J Psychiatry"},{"issue":"5","key":"1294_CR136","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1177\/2045125314542098","volume":"4","author":"AK Das","year":"2014","unstructured":"Das AK, Malik A, Haddad PM. A qualitative study of the attitudes of patients in an early intervention service towards antipsychotic long-acting injections. Ther Adv Psychopharmacol. 2014;4(5):179\u201385. https:\/\/doi.org\/10.1177\/2045125314542098.","journal-title":"Ther Adv Psychopharmacol."},{"key":"1294_CR137","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/1471-244X-13-58","volume":"13","author":"P Geerts","year":"2013","unstructured":"Geerts P, Martinez G, Schreiner A. Attitudes towards the administration of long-acting antipsychotics: a survey of physicians and nurses. BMC Psychiatry. 2013;13:58. https:\/\/doi.org\/10.1186\/1471-244X-13-58.","journal-title":"BMC Psychiatry"},{"issue":"1","key":"1294_CR138","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/1471-244X-9-46","volume":"9","author":"H Ascher-Svanum","year":"2009","unstructured":"Ascher-Svanum H, Peng X, Faries D, Montgomery W, Haddad PM. Treatment patterns and clinical characteristics prior to initiating depot typical antipsychotics for nonadherent schizophrenia patients. BMC Psychiatry. 2009;9(1):46. https:\/\/doi.org\/10.1186\/1471-244X-9-46.","journal-title":"BMC Psychiatry"},{"key":"1294_CR139","doi-asserted-by":"publisher","DOI":"10.1093\/schizbullopen\/sgaf001","author":"D Velligan","year":"2025","unstructured":"Velligan D, Salinas GD, Belcher E, Franzenburg KR, Suett M, Thompson S, et al. Preferences for selecting and initiating long-acting injectable antipsychotic agents for the treatment of patients with schizophrenia: results from the US DECIDE survey. Schizophr Bull Open. 2025. https:\/\/doi.org\/10.1093\/schizbullopen\/sgaf001.","journal-title":"Schizophr Bull Open."},{"key":"1294_CR140","doi-asserted-by":"publisher","first-page":"116460","DOI":"10.1016\/j.psychres.2025.116460","volume":"348","author":"SF Aprile","year":"2025","unstructured":"Aprile SF, Rodolico A, Di Francesco A, Varrasi S, Bighelli I, Castellano S, et al. Oral versus long-acting injectable antipsychotics in schizophrenia spectrum disorders: a systematic review of patients\u2019 subjective experiences. Psychiatry Res. 2025;348:116460. https:\/\/doi.org\/10.1016\/j.psychres.2025.116460.","journal-title":"Psychiatry Res"},{"key":"1294_CR141","doi-asserted-by":"publisher","first-page":"111","DOI":"10.2147\/ndt.s326299","volume":"18","author":"L Citrome","year":"2022","unstructured":"Citrome L, Belcher E, Stacy S, Suett M, Mychaskiw M, Salinas GD. Management of schizophrenia with long-acting injectable antipsychotic medications: an assessment of the educational needs of clinicians. Neuropsychiatr Dis Treat. 2022;18:111\u201323. https:\/\/doi.org\/10.2147\/ndt.s326299.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"6","key":"1294_CR142","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1097\/yic.0000000000000578","volume":"40","author":"A Fagiolini","year":"2025","unstructured":"Fagiolini A, Cuomo A, De Berardis D, Dell\u2019Osso B, Pompili M, Serafini G. Differentiating aspects of oral and long-acting injectable antipsychotic drugs for tailoring the therapy of schizophrenia in clinical practice: a narrative review. Int Clin Psychopharmacol. 2025;40(6):e1\u201313. https:\/\/doi.org\/10.1097\/yic.0000000000000578.","journal-title":"Int Clin Psychopharmacol"},{"key":"1294_CR143","doi-asserted-by":"publisher","DOI":"10.3389\/frhs.2024.1385398","author":"AJ Carroll","year":"2024","unstructured":"Carroll AJ, Robinson DG, Kane JM, Kordon A, Bannon J, Walunas TL, et al. Multi-level barriers and facilitators to implementing evidence-based antipsychotics in the treatment of early phase schizophrenia. Front Health Serv. 2024. https:\/\/doi.org\/10.3389\/frhs.2024.1385398.","journal-title":"Front Health Serv"},{"issue":"3","key":"1294_CR144","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1002\/wps.20567","volume":"17","author":"TS Stroup","year":"2018","unstructured":"Stroup TS, Gray N. Management of common adverse effects of antipsychotic medications. World Psychiatry. 2018;17(3):341\u201356. https:\/\/doi.org\/10.1002\/wps.20567.","journal-title":"World Psychiatry"},{"key":"1294_CR145","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.2147\/ppa.s53795","volume":"7","author":"G Kaplan","year":"2013","unstructured":"Kaplan G, Casoy J, Zummo J. Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophrenia. Patient Prefer Adherence. 2013;7:1171\u201380. https:\/\/doi.org\/10.2147\/ppa.s53795.","journal-title":"Patient Prefer Adherence"},{"key":"1294_CR146","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16010028","author":"M Markowicz-Piasecka","year":"2023","unstructured":"Markowicz-Piasecka M, Kubisiak M, Asendrych-Wicik K, Ko\u0142odziejczyk M, Grzeli\u0144ska J, Fabija\u0144ska M, et al. Long-acting injectable antipsychotics-a review on formulation and in vitro dissolution. Pharmaceutics. 2023. https:\/\/doi.org\/10.3390\/pharmaceutics16010028.","journal-title":"Pharmaceutics"},{"issue":"2","key":"1294_CR147","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1136\/eb-2015-102086","volume":"18","author":"EG Castillo","year":"2015","unstructured":"Castillo EG, Stroup TS. Effectiveness of long-acting injectable antipsychotics: a clinical perspective. Evid Based Ment Health. 2015;18(2):36\u20139. https:\/\/doi.org\/10.1136\/eb-2015-102086.","journal-title":"Evid Based Ment Health"},{"issue":"7","key":"1294_CR148","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1001\/archpsyc.62.7.717","volume":"62","author":"JC Day","year":"2005","unstructured":"Day JC, Bentall RP, Roberts C, Randall F, Rogers A, Cattell D, et al. Attitudes toward antipsychotic medication: the impact of clinical variables and relationships with health professionals. Arch Gen Psychiatry. 2005;62(7):717\u201324. https:\/\/doi.org\/10.1001\/archpsyc.62.7.717.","journal-title":"Arch Gen Psychiatry"},{"issue":"2","key":"1294_CR149","doi-asserted-by":"publisher","first-page":"45605","DOI":"10.4088\/JCP.22m14604","volume":"84","author":"JM Rubio","year":"2023","unstructured":"Rubio JM, Mychaskiw MA, Lim S, Suett M, Wang Y, Tian M, et al. Predictors for initiation of atypical long-acting injectable antipsychotic agents in a commercial claims cohort of individuals with early phase schizophrenia. J Clin Psychiatry. 2023;84(2):45605.","journal-title":"J Clin Psychiatry"},{"key":"1294_CR150","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.21m14272","author":"D Guinart","year":"2022","unstructured":"Guinart D, Varma K, Segal Y, Talasazana N, Correll CU, Kane JM. Reasons for antipsychotic treatment switch: a systematic retrospective review of prescription records and prescriber notes. J Clin Psychiatry. 2022. https:\/\/doi.org\/10.4088\/JCP.21m14272.","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"1294_CR151","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1186\/s12888-022-03846-x","volume":"22","author":"A Keenan","year":"2022","unstructured":"Keenan A, Lin D, Shepherd J, Bailey H, Benson C, Meakin S. Patient-psychiatrist discordance and drivers of prescribing long-acting injectable antipsychotics for schizophrenia management in the real-world: a point-in-time survey. BMC Psychiatry. 2022;22(1):187. https:\/\/doi.org\/10.1186\/s12888-022-03846-x.","journal-title":"BMC Psychiatry"},{"key":"1294_CR152","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.18m12546","author":"JM Kane","year":"2019","unstructured":"Kane JM, Schooler NR, Marcy P, Achtyes ED, Correll CU, Robinson DG. Patients with early phase schizophrenia will accept treatment with sustained-release medication (long-acting injectable antipsychotics): results from the recruitment phase of the PRELAPSE trial. J Clin Psychiatry. 2019. https:\/\/doi.org\/10.4088\/JCP.18m12546.","journal-title":"J Clin Psychiatry"},{"issue":"12","key":"1294_CR153","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.3390\/healthcare11121670","volume":"11","author":"Y-Y Lin","year":"2023","unstructured":"Lin Y-Y, Hou W-L, Lin M-L. Psychiatric nurses\u2019 knowledge and practice barriers to administering long-acting injectable (LAI) antipsychotics in Taiwan: a mixed-methods study. Healthcare. 2023;11(12):1670.","journal-title":"Healthcare"},{"issue":"6","key":"1294_CR154","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1007\/s10597-011-9389-6","volume":"47","author":"DI Velligan","year":"2011","unstructured":"Velligan DI, Medellin E, Draper M, Maples N, Dassori A, Moore TA, et al. Barriers to, and strategies for, starting a long acting injection clinic in a community mental health center. Community Ment Health J. 2011;47(6):654\u20139. https:\/\/doi.org\/10.1007\/s10597-011-9389-6.","journal-title":"Community Ment Health J"},{"issue":"1","key":"1294_CR155","doi-asserted-by":"publisher","DOI":"10.1017\/s1092852925100400","volume":"30","author":"L Citrome","year":"2025","unstructured":"Citrome L. Choosing among the long-acting injectable antipsychotics: an evidence-based pragmatic guide. CNS Spectr. 2025;30(1):e73. https:\/\/doi.org\/10.1017\/s1092852925100400.","journal-title":"CNS Spectr"},{"key":"1294_CR156","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.2147\/ndt.s477674","volume":"20","author":"CU Correll","year":"2024","unstructured":"Correll CU, Rubio JM, Citrome L, Mychaskiw MA, Thompson S, Franzenburg KR, et al. Introducing S.C.O.P.E.\u2122 (schizophrenia clinical outcome scenarios and patient-provider engagement), an interactive digital platform to educate healthcare professionals on schizophrenia care. Neuropsychiatr Dis Treat. 2024;20:1995\u20132010. https:\/\/doi.org\/10.2147\/ndt.s477674.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"1","key":"1294_CR157","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.schres.2012.02.030","volume":"138","author":"R Emsley","year":"2012","unstructured":"Emsley R, Nuamah I, Hough D, Gopal S. Treatment response after relapse in a placebo-controlled maintenance trial in schizophrenia. Schizophr Res. 2012;138(1):29\u201334.","journal-title":"Schizophr Res"},{"issue":"6","key":"1294_CR158","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1038\/s41386-018-0278-3","volume":"44","author":"H Takeuchi","year":"2019","unstructured":"Takeuchi H, Siu C, Remington G, Fervaha G, Zipursky RB, Foussias G, et al. Does relapse contribute to treatment resistance? Antipsychotic response in first- vs. second-episode schizophrenia. Neuropsychopharmacology. 2019;44(6):1036\u201342.","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"1294_CR159","doi-asserted-by":"publisher","first-page":"448","DOI":"10.47626\/1516-4446-2023-3126","volume":"45","author":"E Diniz","year":"2023","unstructured":"Diniz E, Fonseca L, Rocha D, Trevizol A, Cerqueira R, Ortiz B, et al. Treatment resistance in schizophrenia: a meta-analysis of prevalence and correlates. Braz J Psychiatry. 2023;45(5):448\u201358. https:\/\/doi.org\/10.47626\/1516-4446-2023-3126.","journal-title":"Braz J Psychiatry."},{"issue":"4","key":"1294_CR160","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1192\/bjp.184.4.346","volume":"184","author":"S Almond","year":"2004","unstructured":"Almond S, Knapp M, Francois C, Toumi M, Brugha T. Relapse in schizophrenia: costs, clinical outcomes and quality of life. Br J Psychiatry. 2004;184(4):346\u201351.","journal-title":"Br J Psychiatry"},{"issue":"5","key":"1294_CR161","first-page":"42854","volume":"24","author":"D Lin","year":"2022","unstructured":"Lin D, Kim H, Wada K, Aboumrad M, Powell E, Zwain G, et al. Unemployment, homelessness, and other societal outcomes among US veterans with schizophrenia relapse: a retrospective cohort study. Prim Care Companion CNS Disord. 2022;24(5):42854.","journal-title":"Prim Care Companion CNS Disord."},{"issue":"10","key":"1294_CR162","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1007\/s00127-024-02620-6","volume":"59","author":"N Chilman","year":"2024","unstructured":"Chilman N, Laporte D, Dorrington S, Hatch SL, Morgan C, Okoroji C, et al. Understanding social and clinical associations with unemployment for people with schizophrenia and bipolar disorders: large-scale health records study. Soc Psychiatry Psychiatr Epidemiol. 2024;59(10):1709\u201319. https:\/\/doi.org\/10.1007\/s00127-024-02620-6.","journal-title":"Soc Psychiatry Psychiatr Epidemiol"},{"key":"1294_CR163","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11920-017-0756-z","volume":"19","author":"A Caqueo-Ur\u00edzar","year":"2017","unstructured":"Caqueo-Ur\u00edzar A, Rus-Calafell M, Craig TK, Irarrazaval M, Urz\u00faa A, Boyer L, et al. Schizophrenia: impact on family dynamics. Curr Psychiatry Rep. 2017;19:1\u20138.","journal-title":"Curr Psychiatry Rep"},{"key":"1294_CR164","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1007\/s40273-017-0515-3","volume":"35","author":"M Pennington","year":"2017","unstructured":"Pennington M, McCrone P. The cost of relapse in schizophrenia. Pharmacoeconomics. 2017;35:921\u201336.","journal-title":"Pharmacoeconomics"},{"issue":"5","key":"1294_CR165","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.pnpbp.2009.03.034","volume":"33","author":"J Hong","year":"2009","unstructured":"Hong J, Windmeijer F, Novick D, Haro JM, Brown J. The cost of relapse in patients with schizophrenia in the European SOHO (Schizophrenia Outpatient Health Outcomes) study. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33(5):835\u201341.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"7","key":"1294_CR166","doi-asserted-by":"publisher","first-page":"A457","DOI":"10.1016\/j.jval.2014.08.1253","volume":"17","author":"M Pletscher","year":"2014","unstructured":"Pletscher M, Mattli R, Reich O, Von Wyl A, Wieser S. The societal costs of schizophrenia in Switzerland. Value Health. 2014;17(7):A457.","journal-title":"Value Health."},{"issue":"6","key":"1294_CR167","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1176\/appi.ajp.2013.12050674","volume":"170","author":"NC Andreasen","year":"2013","unstructured":"Andreasen NC. Relapse duration, treatment intensity, and brain tissue loss in schizophrenia: a prospective longitudinal MRI study. Am J Psychiatry. 2013;170(6):609\u201315.","journal-title":"Am J Psychiatry"},{"issue":"10","key":"1294_CR168","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1038\/sj.npp.1301347","volume":"32","author":"NE van Haren","year":"2007","unstructured":"van Haren NE, Hulshoff Pol HE, Schnack HG, Cahn W, Mandl RC, Collins DL, et al. Focal gray matter changes in schizophrenia across the course of the illness: a 5-year follow-up study. Neuropsychopharmacology. 2007;32(10):2057\u201366. https:\/\/doi.org\/10.1038\/sj.npp.1301347.","journal-title":"Neuropsychopharmacology"},{"issue":"10327","key":"1294_CR169","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/s0140-6736(21)01997-8","volume":"399","author":"J Schneider-Thoma","year":"2022","unstructured":"Schneider-Thoma J, Chalkou K, D\u00f6rries C, Bighelli I, Ceraso A, Huhn M, et al. Comparative efficacy and tolerability of 32 oral and long-acting injectable antipsychotics for the maintenance treatment of adults with schizophrenia: a systematic review and network meta-analysis. Lancet. 2022;399(10327):824\u201336. https:\/\/doi.org\/10.1016\/s0140-6736(21)01997-8.","journal-title":"Lancet"},{"issue":"5","key":"1294_CR170","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1176\/appi.ajp.2020.20071120","volume":"178","author":"G Ostuzzi","year":"2021","unstructured":"Ostuzzi G, Bertolini F, Del Giovane C, Tedeschi F, Bovo C, Gastaldon C, et al. Maintenance treatment with long-acting injectable antipsychotics for people with nonaffective psychoses: a network meta-analysis. Am J Psychiatry. 2021;178(5):424\u201336. https:\/\/doi.org\/10.1176\/appi.ajp.2020.20071120.","journal-title":"Am J Psychiatry"},{"issue":"6","key":"1294_CR171","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1111\/eip.13202","volume":"16","author":"L Lian","year":"2022","unstructured":"Lian L, Kim DD, Procyshyn RM, Fredrikson DH, C\u00e1zares D, Honer WG, et al. Efficacy of long-acting injectable versus oral antipsychotic drugs in early psychosis: a systematic review and meta-analysis. Early Interv Psychiatry. 2022;16(6):589\u201399. https:\/\/doi.org\/10.1111\/eip.13202.","journal-title":"Early Interv Psychiatry"},{"key":"1294_CR172","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.2147\/ndt.s413371","volume":"19","author":"N Ma","year":"2023","unstructured":"Ma N, Zhang L, Zhang W, He Y, Ye C, Li X. Long-acting injectable antipsychotic treatment for schizophrenia in Asian population: a scoping review. Neuropsychiatr Dis Treat. 2023;19:1987\u20132006. https:\/\/doi.org\/10.2147\/ndt.s413371.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"12","key":"1294_CR173","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/S2215-0366(23)00288-2","volume":"10","author":"JM Kane","year":"2023","unstructured":"Kane JM, Harary E, Eshet R, Tohami O, Weiser M, Leucht S, et al. Efficacy and safety of TV-46000, a long-acting, subcutaneous, injectable formulation of risperidone, for schizophrenia: a randomised clinical trial in the USA and Bulgaria. Lancet Psychiatry. 2023;10(12):934\u201343. https:\/\/doi.org\/10.1016\/S2215-0366(23)00288-2.","journal-title":"Lancet Psychiatry"},{"issue":"12","key":"1294_CR174","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1001\/jamapsychiatry.2020.2076","volume":"77","author":"JM Kane","year":"2020","unstructured":"Kane JM, Schooler NR, Marcy P, Correll CU, Achtyes ED, Gibbons RD, et al. Effect of long-acting injectable antipsychotics vs usual care on time to first hospitalization in early phase schizophrenia: a randomized clinical trial. JAMA Psychiat. 2020;77(12):1217\u201324.","journal-title":"JAMA Psychiat"},{"issue":"10","key":"1294_CR175","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.18553\/jmcp.2022.28.10.1130","volume":"28","author":"S Kheloussi","year":"2022","unstructured":"Kheloussi S, Oberlin J Jr, Trauger M, Testa ND. Clinical and economic impact of long-acting injectable antipsychotics in patients previously treated with short-acting oral antipsychotics. J Manag Care Spec Pharm. 2022;28(10):1130\u20137. https:\/\/doi.org\/10.18553\/jmcp.2022.28.10.1130.","journal-title":"J Manag Care Spec Pharm"},{"issue":"7","key":"1294_CR176","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1001\/jamapsychiatry.2017.1322","volume":"74","author":"J Tiihonen","year":"2017","unstructured":"Tiihonen J, Mittendorfer-Rutz E, Majak M, Meht\u00e4l\u00e4 J, Hoti F, Jedenius E, et al. Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29 823 patients with schizophrenia. JAMA Psychiat. 2017;74(7):686\u201393. https:\/\/doi.org\/10.1001\/jamapsychiatry.2017.1322.","journal-title":"JAMA Psychiat"},{"issue":"5","key":"1294_CR177","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1177\/0004867416641195","volume":"50","author":"C Galletly","year":"2016","unstructured":"Galletly C, Castle D, Dark F, Humberstone V, Jablensky A, Killackey E, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders. Aust N Z J Psychiatry. 2016;50(5):410\u201372.","journal-title":"Aust N Z J Psychiatry"},{"key":"1294_CR178","unstructured":"Canadian Consortium for early intervention in psychosis: initiation of treatment for early phase psychotic disorders order set 2023 [cited 2025 17 March]. https:\/\/www.epicanada.org\/_files\/ugd\/9f0189_4fb5549c858b45fba6e6e5d5079fd67a.pdf."},{"issue":"1","key":"1294_CR179","doi-asserted-by":"publisher","DOI":"10.1192\/j.eurpsy.2022.2315","volume":"65","author":"A Vita","year":"2022","unstructured":"Vita A, Gaebel W, Mucci A, Sachs G, Barlati S, Giordano GM, et al. European Psychiatric Association guidance on treatment of cognitive impairment in schizophrenia. Eur Psychiatry. 2022;65(1):e57. https:\/\/doi.org\/10.1192\/j.eurpsy.2022.2315.","journal-title":"Eur Psychiatry"},{"key":"1294_CR180","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1186\/1471-244x-13-340","volume":"13","author":"PM Llorca","year":"2013","unstructured":"Llorca PM, Abbar M, Courtet P, Guillaume S, Lancrenon S, Samalin L. Guidelines for the use and management of long-acting injectable antipsychotics in serious mental illness. BMC Psychiatry. 2013;13:340. https:\/\/doi.org\/10.1186\/1471-244x-13-340.","journal-title":"BMC Psychiatry"},{"issue":"1","key":"1294_CR181","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1002\/wps.20706","volume":"19","author":"W Gaebel","year":"2020","unstructured":"Gaebel W, Falkai P, Hasan A. The revised German evidence- and consensus-based schizophrenia guideline. World Psychiatry. 2020;19(1):117.","journal-title":"World Psychiatry"},{"issue":"Suppl 1","key":"1294_CR182","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.4103\/0019-5545.196972","volume":"59","author":"S Grover","year":"2017","unstructured":"Grover S, Chakrabarti S, Kulhara P, Avasthi A. Clinical practice guidelines for management of schizophrenia. Indian J Psychiatry. 2017;59(Suppl 1):S19-s33. https:\/\/doi.org\/10.4103\/0019-5545.196972.","journal-title":"Indian J Psychiatry."},{"key":"1294_CR183","unstructured":"Ministry of Health (Kenya). National clinical guidelines for management of common mental disorders. Nairobi: Division of Mental Health, Ministry of Health; 2024. [cited 2025 11 November]. https:\/\/www.mntrh.go.ke\/sites\/default\/files\/2024-10\/NATIONAL%20CLINICAL%20GUIDELINES%20NEW.pdf."},{"issue":"6","key":"1294_CR184","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1093\/schbul\/sbae043","volume":"50","author":"C Lorenz","year":"2024","unstructured":"Lorenz C, Bighelli I, Hanna F, Akhtar A, Leucht S. Update of the World Health Organization\u2019s mental health gap action programme guideline for psychoses (including schizophrenia). Schizophr Bull. 2024;50(6):1310\u201325. https:\/\/doi.org\/10.1093\/schbul\/sbae043.","journal-title":"Schizophr Bull"},{"issue":"7","key":"1294_CR185","first-page":"521","volume":"52","author":"S Verma","year":"2011","unstructured":"Verma S, Chan LL, Chee KS, Chen H, Chin SA, Chong SA, et al. Ministry of Health clinical practice guidelines: schizophrenia. Singapore Med J. 2011;52(7):521\u20135 (quiz 6).","journal-title":"Singapore Med J"},{"key":"1294_CR186","unstructured":"National Department of Health, South Africa. Essential drugs programme. Hospital level (adults) standard treatment guidelines and essential medicines list. 5th ed. [cited 2025 12 November]. https:\/\/knowledgehub.health.gov.za\/system\/files\/elibdownloads\/2023-04\/Hospital%2520Level%2520%2528Adult%2529%25202019_v2.0.pdf."},{"issue":"Suppl 1","key":"1294_CR187","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.29399\/npa.27441","volume":"58","author":"U Kirli","year":"2021","unstructured":"Kirli U, Alptek\u0131n K. Pharmacotherapy of schizophrenia in acute and maintenance phase. Noro Psikiyatr Ars. 2021;58(Suppl 1):S17-s23. https:\/\/doi.org\/10.29399\/npa.27441.","journal-title":"Noro Psikiyatr Ars."},{"key":"1294_CR188","unstructured":"National Institute for Health and Care Excellence: Guidelines. Psychosis and schizophrenia in adults: prevention and management. London: National Institute for Health and Care Excellence (NICE). Copyright \u00a9 NICE 2024; 2014."},{"issue":"9","key":"1294_CR189","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1176\/appi.ajp.2020.177901","volume":"177","author":"GA Keepers","year":"2020","unstructured":"Keepers GA, Fochtmann LJ, Anzia JM, Benjamin S, Lyness JM, Mojtabai R, et al. The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry. 2020;177(9):868\u201372. https:\/\/doi.org\/10.1176\/appi.ajp.2020.177901.","journal-title":"Am J Psychiatry"},{"issue":"1","key":"1294_CR190","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1093\/schbul\/sbp130","volume":"36","author":"J Kreyenbuhl","year":"2010","unstructured":"Kreyenbuhl J, Buchanan RW, Dickerson FB, Dixon LB. The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2009. Schizophr Bull. 2010;36(1):94\u2013103. https:\/\/doi.org\/10.1093\/schbul\/sbp130.","journal-title":"Schizophr Bull"},{"key":"1294_CR191","unstructured":"National Council for Mental Wellbeing. Guide to long-acting medications for providers and organizations. [cited 2025 April 16]; Published 2019. https:\/\/www.thenationalcouncil.org\/resources\/guide-to-long-acting-medications\/."},{"issue":"2","key":"1294_CR192","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1080\/13651501.2017.1291839","volume":"21","author":"A Hasan","year":"2017","unstructured":"Hasan A, Falkai P, Wobrock T, Lieberman J, Glenth\u00f8j B, Gattaz WF, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia\u2014a short version for primary care. Int J Psychiatry Clin Pract. 2017;21(2):82\u201390. https:\/\/doi.org\/10.1080\/13651501.2017.1291839.","journal-title":"Int J Psychiatry Clin Pract"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-026-01294-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-026-01294-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-026-01294-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T11:02:53Z","timestamp":1782385373000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-026-01294-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,27]]},"references-count":192,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1294"],"URL":"https:\/\/doi.org\/10.1007\/s40263-026-01294-9","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,27]]},"assertion":[{"value":"4 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Duplicated footnote has been removed from Figure 2 in the original publication.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr Correll reports that he has been a consultant and\/or advisor to or has received honoraria from AbbVie, Alkermes, Allergan, Angelini, Aristo, Autobahn, Boehringer-Ingelheim, Bristol-Meyers Squibb, Cardio Diagnostics, Cerevel, CNX Therapeutics, Compass Pathways, Darnitsa, Delpor, Denovo, Draig, Eli Lilly, Eumentis Therapeutics, Gedeon Richter, Hikma, Holmusk, IntraCellular Therapies, Jamjoom Pharma, Johnson & Johnson, Karuna, LB Pharma, Lundbeck, MedInCell, MedLink, Merck, Mindpax, Mitsubishi Tanabe Pharma, Maplight, Mylan, Neumora Therapeutics, Neuraxpharm, Neurocrine, Neurelis, Newron, Noven, Novo Nordisk, Otsuka, PPD Biotech, Recordati, Relmada, Response Pharmaceutical, Reviva, Rovi, Saladax, Sanofi, Seqirus, Servier, Sumitomo Pharma America, Sunovion, Sun Pharma, Supernus, Tabuk, Takeda, Teva, Terran, Tolmar, Vertex, Viatris and Xenon Pharmaceuticals. He provided expert testimony for Johnson & Johnson, Lundbeck and Otsuka. He served on a Data Safety Monitoring Board for Compass Pathways, IntraCellular Therapies, Relmada, Reviva, Rovi. He has received grant support from Boehringer-Ingelheim, Johnson & Johnson and Takeda. He received royalties from UpToDate and is also a stock option holder of Cardio Diagnostics, Kuleon Biosciences, LB Pharma, Medlink, Mindpax, Quantic, and Terran. Dr Sanchez reports that he has been a consultant and\/or advisor to or has received honoraria from Angelini, Casen-Recordati, Johnson & Johnson, Lundbeck, Osakidetza, Otsuka, Rovi, and University of Deusto. All the other authors are employees of Johnson & Johnson and may hold company stocks or stock options in Johnson & Johnson.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Conception and design: all authors. Acquisition of data: all authors. Data analysis and interpretation: all authors. Manuscript writing and editing: all authors. Final approval of manuscript: all authors. Accountable for all aspects of the work: all authors. All authors met ICMJE criteria and all those who fulfilled those criteria are listed as authors. All authors had access to the study data, provided direction and comments on the manuscript, made the final decision about where to publish these data, and approved submission to the journal.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}